On ECHEMI
Home > Drugs > Xuchang Future Pharmaceutical Co., Ltd.
Xuchang Future Pharmaceutical Co., Ltd.
  • Founded in:

    1999-04-28
  • Country:

    China China
  • Address:

    No. 3888, Xuyou East Road, Dongcheng District, Xuchang City
  • Tax NO.:

    9141100071128293X8
  • Registered Funds:

    255 million yuan
  • Website:

  • Email:

Related Drugs
Ciclopirox Olamine
Each gram of this product contains 10 mg of the main ingredient, ciclopirox olamine. The excipients are octadecyl alcohol, stearic acid, white vaseline, Span-60, dimethicone, propylene glycol, glycerin, Tween-80, benzoic acid, menthol, S-40, isopropyl palmitate, lactic acid, medicinal ethanol, water
Name Description Content CAS NO. Registered Holders
Ciclopirox ethanolamine

Ciclopirox is a broad-spectrum antifungal drug that has antifungal effects on pathogenic fungi that can cause nail fungus infections.

More

Ciclopirox is a broad-spectrum antifungal drug that has antifungal effects on pathogenic fungi that can cause nail fungus infections.

10mg 41621-49-2 12
Chlordiazepoxide Tablets
Name Description Content CAS NO. Registered Holders
Chlordiazepoxide

Poisoning symptoms: When poisoned by a large dose, coma, hypotension, respiratory depression and bradycardia may occur. Treatment: Immediately induce vomiting, gastric lavage and catharsis to eliminate the drug, and give symptomatic treatment and supportive therapy according to the condition.

More

Poisoning symptoms: When poisoned by a large dose, coma, hypotension, respiratory depression and bradycardia may occur. Treatment: Immediately induce vomiting, gastric lavage and catharsis to eliminate the drug, and give symptomatic treatment and supportive therapy according to the condition.

0
Indomethacin Tablets
The main ingredients of this product and their chemical names are: The main ingredient of this product is indomethacin, and its chemical name is 2-methyl-1-(4-chlorobenzoyl)-5-methoxy-1H-indole-3-acetic acid.
Name Description Content CAS NO. Registered Holders
Indometacin

This product has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.

More

This product has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.

53-86-1 23
Proglumide Tablets
Proglumide. Its chemical name is (plusmn;)-5-dipropylamino-4-benzoylamino-5-oxo-pentanoic acid.
Name Description Content CAS NO. Registered Holders
Proglumide

This product is a gastrin receptor antagonist, which can significantly inhibit the secretion of gastric acid and pepsin caused by gastrin, but has no significant effect on the gastric acid secretion caused by histamine and vagus nerve stimulation. It can increase the content of hexosamine in the gastric mucosa, promote glycoprotein synthesis, and protect and promote the healing of the gastric mucosa. It has a choleretic effect, and can prevent stone formation and improve bile duct function by stimulating bile acid-independent bile secretion, changing the stone-forming factors in bile, and antagonizing CCK. The use of this product to treat peptic ulcers and gastritis does not cause rebound gastric acid secretion, and gastric acid secretion can remain at a normal level for up to half a year after the treatment is terminated.

More

This product is a gastrin receptor antagonist, which can significantly inhibit the secretion of gastric acid and pepsin caused by gastrin, but has no significant effect on the gastric acid secretion caused by histamine and vagus nerve stimulation. It can increase the content of hexosamine in the gastric mucosa, promote glycoprotein synthesis, and protect and promote the healing of the gastric mucosa. It has a choleretic effect, and can prevent stone formation and improve bile duct function by stimulating bile acid-independent bile secretion, changing the stone-forming factors in bile, and antagonizing CCK. The use of this product to treat peptic ulcers and gastritis does not cause rebound gastric acid secretion, and gastric acid secretion can remain at a normal level for up to half a year after the treatment is terminated.

6620-60-6 7
Glucuronolactone
Name Description Content CAS NO. Registered Holders
D-Glucurone

Extract from the above information

More

Extract from the above information

32449-92-6 6
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.